Overcoming the unmet need of Richter transformation: the use of pirtobrutinib
-
Published:2024-09
Issue:9
Volume:11
Page:e636-e637
-
ISSN:2352-3026
-
Container-title:The Lancet Haematology
-
language:en
-
Short-container-title:The Lancet Haematology
Reference10 articles.
1. Improved survival of patients with chronic lymphocytic leukemia between 1998–2022, including the era of target therapies with BCL2 and BTK inhibitors;Tadmor;Anticancer Res,2024
2. Successful treatment of Richter transformation with ibrutinib in a patient with chronic lymphocytic leukemia following allogeneic hematopoietic stem cell transplant;Master;Case Rep Oncol,2017
3. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1/2 study;Eyre;Lancet Haematol,2021
4. Zanubrutinib, alone and in combination with tislelizumab, for the treatment of Richter transformation of chronic lymphocytic leukemia;Tam;HemaSphere,2023
5. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL;Jain;Blood Adv,2023